Company intelligence / Profile preview

Adamas Pharmaceuticals, Inc.

Emeryville, California, United Statesadamaspharma.com ↗

Ownership: Public · ADMS
Employees: ~44
Development stage: Other

Overview

Adamas has FDA-approved products including GOCOVRI (amantadine extended release) for treatment of dyskinesia in Parkinson's disease patients and as an adjunctive treatment to levodopa/carbidopa in Parkinson's disease patients experiencing OFF episodes. The company also has OSMOLEX ER for treating Parkinson's disease. Their ADS-5102 showed significant improvement in walking speed for multiple sclerosis patients in Phase 2 trials.

Therapeutic areas: Neurology
Modalities: Small molecules
Industry: Biotech

Beyond the preview

Go deeper on Adamas Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Adamas Pharmaceuticals, Inc..